IN THE NATURE OF ABRIDGED PROSPECTUS-MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS	
(Scan this QR Code to View the RHP)	This is an abridged prospectus containing salient features of the Red Herring Prospectus dated May 06, 2026 (the "RHP"). You are encouraged to read greater details available in the RHP, this abridged prospectus ("Abridged Prospectus") and the general information document for investing in public offer ("GID") undertaken through the Book Building Process before applying in the Issue (as defined below). The investors are advised to retain a copy of the RHP/Abridged Prospectus for their future reference. You may also download the RHP from the website of the Book Running Lead Manager ("BRLM") at www.cumulativecapital.group and from the website of the Company at www.goldlinepharma.in. References below to page numbers are to page numbers of the Red Herring Prospectus dated May 06, 2026. Unless otherwise specified all capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.
THIS ABRIDGED PROSPECTUS CONSISTS OF 4 PAGES OF BID CUM APPLICATION FORM ALONG WITH INSTRUCTIONS AND 7 PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.	
You may obtain a physical copy of the Bid-cum-Application Form and the RHP from Stock Exchange, Syndicate Member, Registrar to Issue, Registrar and Share Transfer Agents, Collecting Depository Participants, Registered Brokers, Bankers to the Issue, investors' association of Self Certified Syndicate Banks. You may also download the RHP from the websites of Securities and Exchange Board of India ("SEBI") at www.sebi.gov.in , BRLM at www.cumulativecapital.group and BSE Limited ("Stock Exchange" or "BSE") at www.bsesme.com	

Adds life to health
Goldline Pharmaceutical Limited

GOLDLINE PHARMACEUTICAL LIMITED

Corporate Identity Number: U51397MH2004PLC147806

Date of Incorporation: August 02,2004

REGISTERED OFFICE	CONTACT PERSON	TELEPHONE AND EMAIL	WEBSITE
103, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur – 440 015, Maharashtra, India.	Ruchi Sanket Modi, Company Secretary and Compliance Officer	**Tel:** +91 712 278 6666 **Email:** info@goldlinepharma.in	www.goldlinepharma.in
PROMOTERS OF OUR COMPANY: AMOL LAXMIKANT MUJUMDAR AND SWAPAN PREMPRAKASH KHANDELWAL			

DETAILS OF THE ISSUE

TYPE	FRESH ISSUE SIZE (IN ₹ LAKHS)	OFS SIZE (BY NO. OF SHARES OR BY AMOUNT IN ₹)	TOTAL ISSUE SIZE	ELIGIBILITY
Fresh Issue	Upto 27,00,000 Equity Shares aggregating to ₹ [●] Lakhs	Nil	Upto 27,00,000 Equity Shares aggregating to ₹ [●] Lakhs	The Issue is being made pursuant to Regulation 229 (2) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("***SEBI ICDR Regulations***"). For further details, see "*Other Regulatory and Statutory Disclosures – Eligibility for the Issue*" on page 262. For details of share reservation among NIIs and Individual Investors, see "*Issue Structure*" on page 287.
DETAILS OF OFFER FOR SALE, SELLING SHAREHOLDERS AND THEIR AVERAGE COST OF ACQUISITION – NOT APPLICABLE AS THE ENTIRE ISSUE CONSTITUTES FRESH ISSUE OF EQUITY SHARES				

1. Summary of the primary business

a. Business Overview - Products and Services

We are engaged in the business of marketing pharmaceutical products under the brand name "Goldline." Our product portfolio is organized into five distinct segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. The pharmaceutical products marketed under the "Goldline" brand are not manufactured by our Company. Instead, we enter into contractual arrangements with third-party manufacturers, who produce the products based on our market research, demand analysis, and specifications. These contractual arrangements ensure that all products meet the requisite quality standards and regulatory norms.

b. Industries Served and Typical Customer

The products are marketed and sold exclusively under the "Goldline" brand. Our customers primarily comprise distributors, who further supply to retailers and wholesalers, forming the main channel of distribution to the end-users. Presently, we maintain contractual arrangements with 15 manufacturers and 8 distributors, ensuring a stable supply chain and consistent market presence.

c. Segment Reporting and Revenue Contribution

The Company primarily operates in one segment which comprises of Selling and Distribution of Medicines. Hence, separate business segment information is not applicable. For further details, please see "*Restated Financial Information" beginning* on page 202.

d. Key Geographies

Our operations are based out of limited region like Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, Bihar, Chhattisgarh, Uttar Pradesh and Goa.

e. Revenue Concentration Among Top 10 Customers

The table below sets forth details of our revenue from operations generated from top 10 customers in each of the respective periods indicated:

(Amount in lakhs)

Particulars*	As on December 31, 2025		As on March 31, 2025		As on March 31, 2024		As on March 31, 2023	
	Amount	% of total Revenue	Amount	% of total Revenue	Amount	% of total Revenue	% of total Revenue	Amount
Top 1 customer	755.45	35.29	1087.15	38.75	949.31	40.28	754.46	38.01
Top 3 customers	1376.94	64.32	1696.46	60.47	1562.58	66.31	1218.43	61.39
Top 5 customers	1653.85	77.26	2198.58	78.36	1860.42	78.94	1558.66	78.53
Top 10 customers	1913.46	89.39	2558.39	91.19	2084.26	88.44	1762.90	88.82

* *Revenue from Operations*

For complete break up of revenue from each top 10 customers, please refer to the section titled Risk Factors beginning on page 16.

f. Key manufacturing or other Facilities

The Company does not own any manufacturing facilities, as it is primarily engaged in the business of marketing pharmaceutical products under the brand name "Goldline."

<u>Strengths</u>

The Company's key strengths include its experienced promoters and management team, Asset-light Business Model and Competitive Products:, a Scalable Business Model, Wide and Diverse range of Product offerings, strong supplier and Vendor Relationships, and an established Business Network that enables growth with relatively low capital requirements.

For further and complete information, see "*Our Business*" beginning on page 124.

<u>Strategies</u>

The Company's strategy focuses on enhancing operational efficiency, expanding its product portfolio and customer base, achieving higher levels of customer satisfaction, and strengthening brand awareness and credibility.

For further and complete information, see "*Our Business*" beginning on page 124.

2. Summary of the Industry

The Indian pharmaceutical industry is the world's 3rd largest by volume of production and plays a significant role globally. India is a global leader in the supply of DPT, BCG, and Measles vaccines and one of the largest suppliers of low-cost vaccines in the world. Indian manufacturers account for 60 percent of the vaccine supplies to UNICEF, contributing 40 to 70 percent of the WHO demand for Diphtheria, Tetanus and Pertussis (DPT) and Bacillus Calmette–Guérin (BCG) vaccines, and 90 percent of the WHO demand for the measles vaccine. India has the highest number of United States Food and Drug Administration (USFDA) compliant pharma plants outside of the USA. There are 500 API manufacturers contributing about 8% to the global API Industry. India is the largest supplier of generic medicines, with a 20% share in the global supply by manufacturing 60,000 different generic brands across 60 therapeutic categories.

For further information, see "*Industry Overview*" beginning on page 103.

3. Promoters

The Promoters of our Company are *Amol Laxmikant Mujumdar* and *Swapan Premprakash Khandelwal*.

Sr. No.	Name	Individual/Corporate	Experience and Educational Qualification / Corporate Information
1.	Amol Laxmikant Mujumdar	Individual	He holds a bachelor's degree in pharmacy from Nagpur University He holds an experience of more than three decades of experience in sales, marketing and business development.
2.	Swapan Premprakash Khandelwal	Individual	He has passed the degree examination for bachelor's degree in engineering (electronic and instrumentation) organised by Devi Ahilya Vishwavidyalaya, Indore. He has been associated with our Company since April 11, 2011 and has more than two decades of experience in business management

For further information, see "*Promoters and Promoter Group*" beginning on page 193.

4. Objects of the Issue

Issue of up to 27,00,000 Equity Shares for cash at an Issue Price of ₹[●] per Equity Share (including a premium of ₹[●] per Equity Share) aggregating up to ₹ [●] Lakhs. Our Company plans to use the funds raised from this issue for the following key purposes and to gain the benefits of listing on the BSE SME Exchange. This includes improving our brand visibility and creating a public market for our equity shares in India:

1. Repayment of all or a portion of certain outstanding borrowings availed by our Company;
2. General corporate purposes ; and
3. Issue related expenses

(Collectively referred as the "Objects")
^*subject to finalisation of basis of allotment*

For further information, see "*Objects of the Issue*" beginning on page 86.

5. The shareholding pattern of our Promoters, Promoter Group and top 10 additional Shareholders before and after the Issue as at allotment is set forth below:

Sr. No.	Name of the Shareholders	Pre-Issue		Post - Issue	
		Number of Equity Shares	% of Pre-Issue Equity Share Capital	Number of Equity Shares	% of Post-Issue Equity Share Capital
Promoter					
1	Amol Laxmikant Mujumdar	27,49,988	39.85%	[●]	[●]
2	Swapan Premprakash Khandelwal	27,49,988	39.85%	[●]	[●]
Total – A		**54,99,976**	**79.70%**	[●]	[●]
Promoter Group					
3	Asha Swapan Khandelwal	3	Negligible	[●]	[●]
4	Aishwarya Amol Mujumdar	3	Negligible	[●]	[●]
Total – B		**6**	**Negligible**	[●]	[●]
Top 10 additional shareholders					
5.	Sumit Bilgaiyan	6,75,000	9.78%	[●]	[●]
6.	Priya Chandrakant Jalgaonkar	2,25,000	3.26%	[●]	[●]
7.	SGMP Management Consultancy Private Limited	1,90,000	2.75%	[●]	[●]
8.	Meena Nayan Patel	1,00,000	1.45%	[●]	[●]
9.	Charmi Nayanbhai Patel	62,000	0.90%	[●]	[●]
10.	Abhisha Ripal Patel	54,000	0.78%	[●]	[●]
11.	Suyog Shrikant Nildawar	50,000	0.72%	[●]	[●]
12.	Patel Reema	20,000	0.29%	[●]	[●]
13.	Krunal Hareshbhai Shirshikar	14,000	0.20%	[●]	[●]
14.	Gajanan Narayan Janbhor	10,000	0.14%	[●]	[●]
Total – C		**14,00,000**	**20.27%**	[●]	[●]
Total (A+B+C)		**68,99,982**	**99.97%**	[●]	[●]

Note:
1) *There are 2 Promoter Group shareholders*
2) *Includes all options that have been exercised until date of prospectus and any transfers of equity shares by existing shareholders after the date of the pre-issue and price band advertisement until date of prospectus.*
3) *Based on the Issue price of ₹ [●] and subject to finalization of the basis of allotment.*

For further details, see "*Capital Structure*" beginning on page 72.

6. Summary of Restated Financial Information

(Amount in lakhs except percentages)

Particulars	As at and for the nine-month period ended December 31, 2025*	As at and for Financial Year ended March 31, 2025	As at and for Financial Year ended March 31, 2024	As at and for Financial Year ended March 31, 2023
Equity share capital	870.7	870.7	410.7	380.7
Net worth	1,235.56	1,034.94	786.34	589.04
Revenue from Operations	2,140.63	2,805.57	2,356.60	1,984.84
EBITDA	415.55	583.01	430.11	219.45
Net Profit after tax	222.31	283.22	180.40	25.66
Basic Earnings per Equity Share	3.22	4.10	3.01	0.43
Diluted earnings per Equity Share	3.22	4.10	3.01	0.43
Return on Net Worth (%)	17.99	27.37	22.94	4.36
Net Asset Value per Equity Share (in ₹)	15.29	12.38	10.09	6.81
Total borrowings	947.06	1,103.44	1,113.01	1,082.92
Net cash generated from/ (used in) operating activities	232.23	232.14	292.24	239.12
Net cash generated from / (used in) investing activities	(5.26)	16.23	(110.88)	(103.49)
Net cash generated from/ (used in) financing activities	(274.78)	(203.38)	(107.78)	(144.31)

Not annualized

7. Summary of Key Performance Indicators

Key Operational and Financial KPIs of our Company

Financial Metrics	As at and for the year/period ended			
	December 31, 2025	March 31, 2025	March 31, 2024	March 31, 2023
Revenue From operations[(a)] (₹ in Lakhs)	2,140.63	2,805.57	2,356.60	1,984.84
Total revenue[(b)] (₹ in Lakhs)	2,140.74	2,805.57	2,356.60	1,984.85
EBITDA[(c)] (₹ in Lakhs)	415.55	583.01	430.11	219.45
EBITDA Margin[(d)] (%)	19.41	20.78	18.25	11.06
Profit after tax[(e)] (₹ in Lakhs)	222.31	283.22	180.40	25.66
PAT Margin[(f)] (%)	10.38	10.09	7.66	1.29
Return on Equity[(g)] (ROE) (%)	21.02	35.83	31.31	0.90
Debt To Equity Ratio[(h)]	1.07	1.50	2.14	3.09
Interest Coverage Ratio[(i)]	4.11	3.24	2.57	1.25
Return on Capital Employed[(j)] (ROCE) (%)	24.22	38.45	32.40	19.43
Current Ratio[(k)]	2.24	1.98	1.92	1.87
Net Capital Turnover Ratio[(l)]	1.57	2.42	2.53	2.54

Source: The Figure has been certified by B Shroff & Co., Chartered Accountants pursuant to their certificate dated May 04, 2026.

Notes:

a) *Revenue from Operations means the Revenue from Operations as appearing in the Restated Financial Statements.*
b) *EBITDA refers to earnings before interest, taxes, depreciation, amortisation, gain or loss from discontinued operations and exceptional items. EBITDA excludes other income but includes reversal of provision of doubtful debts.*
c) *EBITDA Margin refers to EBITDA during a given period as a percentage of revenue from operations during that period.*
d) *Net Profit Ratio/Margin quantifies our efficiency in generating profits from our revenue and is calculated by dividing our net profit after taxes but before other comprehensive income by our revenue from operations.*
e) *Return on equity (RoE) is equal to Net profit after taxes divided by average shareholder's equity excluding preference share capital.*
f) *Debt to equity ratio is calculated by dividing the debt (i.e., borrowings (current and non-current) and current maturities of long-term-borrowings) including*

preference share capital by total equity (which includes issued equity share capital and all other equity reserves).

g) *Interest Coverage Ratio measures our ability to make interest payments from available earnings and is calculated by dividing EBIT by finance cost.*
h) *RoCE (Return on Capital Employed) (%) is calculated as profit before tax plus finance costs less other income divided by total equity plus non-current liabilities.*
i) *Current Ratio is a liquidity ratio that measures our ability to pay short-term obligations (those which are due within one year) and is calculated by dividing the current assets by current liabilities.*
j) *Net Capital Turnover Ratio quantifies our effectiveness in utilizing our working capital and is calculated by dividing our revenue from operations by our working capital (i.e., current assets less current liabilities).*

8. Risk Factors

The following are the top 10 internal risk factors as disclosed in the RHP:

1. We rely entirely on third-party contract manufacturers for the manufacturing of our pharmaceutical products, and any failure or inability of such manufacturers to meet quality, regulatory, delivery or capacity requirements could adversely affect our business, results of operations and financial condition

2. The Company has experienced delays in filing e-forms with the Registrar of Companies (RoC) in the past, resulting in the payment of late fees. Further, there have also been instances of erroneous filings made by our Company in the past. While no regulatory actions or penalties have been imposed to date except below mentioned, there is no assurance that such actions will not be levied in the future. The Company cannot guarantee that similar delays will not occur in the future, and if regulatory authorities impose penalties or take punitive actions against the Company or its directors/officers, it could negatively affect the Company's business and financial condition.

3. Our commercial success is largely dependent upon our ability to analyse the market of new pharmaceutical products, Failure of which may have an adverse impact on our revenue and profitability

4. There have been instances of delays in payment of statutory dues, i.e. GST by the Company. In case of any delay in payment of statutory due in future by our Company, the Regulatory Authorities may impose monetary penalties on us or take certain punitive actions against our Company in relation to the same which may have adverse impact on our business, financial condition and results of operations

5. We depend on our distributors for a significant portion of our revenue, and any decrease in revenues or sales from any one of our key intermediaries may adversely affect our business and results of operations. Our Company has a distribution network of 8 distributors and is dependent on these distributors for a significant portion of its revenue. If we are unable to maintain our relationship with such customers or if there is a reduction in their demand for our products, our business, results of operations and financial condition will be materially and adversely affected

6. There are outstanding litigations involving our Company, Promoters, Directors, Key Managerial Personnel, Senior Management and Group Companies, if determined adversely, may adversely affect our business and financial condition

7. Our Promoter Group entities Numerius Healthcare Private Limited, Nucleage Lifescience Private Limited and Nucleage Pharma Solutions Private Limited have conflicts of interest as they are engaged in similar business and may compete with us

8. We derive a significant portion of our revenue from certain of our products. If sales volume or price of such products declines in the future, or if we are unable to sell such products for any reason, our business, financial condition, cash flows and results of operations could be adversely affected.

9. We operate in limited geographies for a significant portion of our revenue and also depends on limited number of customers for our revenue from operations

10. Our Company had negative cash flows in the past years, details of which are given below. Sustained negative cash flow could impact our growth and business

For further details of the risks applicable to us, see "*Risk Factors*" beginning on page 16. Investors are advised to read the risk factors carefully before making an investment decision in the Issue.

9. Details of weighted average cost of acquisition of Equity Shares of our Promoters

The weighted average cost of acquisition of Equity Shares of our Promoters are as follows:

S. No.	Name of the Promoter	Number of Equity Shares held as on date	Weighted Average cost of acquisition ("WACA") per Equity Share (in ₹)	WACA per Equity Shares acquired in last three years (in ₹)	WACA per Equity Shares acquired in last one year (in ₹)
1.	Amol Laxmikant Mujumdar	27,49,988	0	0	0
2.	Swapan Khandelwal	27,49,988	0	0	0

10. Board of Directors and Key Managerial Personnel

The names and designations of members of the Board of Directors and Key Managerial Personnel are set forth below:

S. No.	Name	Designation
Board of Directors		
1.	Amol Laxmikant Mujumdar	Chairman and Managing Director
2.	Swapan Premprakash Khandelwal	Whole-Time Director
3.	Prashant Shrikrishna Karkare	Executive Director
4.	Avinash Pandurang Ambulkar	Executive Director
5.	Prashant Vithalrao Rahate	Non-Executive Director
6.	Mehul Hari Ranade	Independent Director
7.	Renuka Saurabh Borole	Independent Director
8.	Shraddha Kiran Kulkarni	Independent Director
Key Managerial Personnel		
1.	Amol Laxmikant Mujumdar	Chairman and Managing Director
2.	Ruchi Sanket Modi	Company Secretary and Compliance Officer
3.	Dipti Sharad Bhusari	Chief Financial Officer

For further details, see "*Our Management*" beginning on page 176.

11. Auditor Qualifications

The Statutory Auditors of our Company have not expressed any qualification, reservation, adverse remark, matter of emphasis, or other observation on our financial statements for the periods covered in the Red Herring Prospectus.

12. Summary table of outstanding litigations

A summary of outstanding litigation proceedings involving our Company, Promoters, Directors, Key Managerial Personnel and members of Senior Management, as on the date of the Red Herring Prospectus in terms of the SEBI ICDR Regulations is provided below:

Name of Entity	Criminal Proceedings	Tax Proceedings	Statutory or Regulatory Proceedings	Disciplinary actions by the SEBI or Stock Exchanges against our Promoter	Material Civil Litigations	Aggregate amount involved (₹ in Lakhs)
Company						
By the Company	NIL	NIL	NIL	NIL	NIL	NA
Against the Company	NIL	4	1	NIL	NIL	342.68
The Promoters						
By the Promoters	NIL	NIL	NIL	NIL	NIL	NA
Against the Promoters	1	NIL	NIL	NIL	NIL	Not Quantifiable
The Directors (other than Promoters)						
By our Directors	1	NIL	NIL	NIL	NIL	1.85
Against the Directors	1	NIL	NIL	NIL	NIL	Not Quantifiable
KMPs and SMPs (excluding MD and WTD)						
By the KMPs/SMPs	NIL	NA	NIL	NIL	NIL	NIL
Against the KMPs/SMPs	NIL	NA	NIL	NIL	NIL	NIL

A. *Brief Details of top 5 Material outstanding litigation against the Company and Amount involved - **NIL***

B. *Regulatory Action, if any–- disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any- **NIL***

C. *Brief details of outstanding criminal proceedings against Promoters **-1***

An FIR bearing No. 0315 dated August 24, 2018 was registered at Police Station Navghar, Thane (Rural) under Sections 18(c), 18(a)(vi) and 17 read with Rules 85 and 104-A of the Drugs and Cosmetics Act, 1940 and Sections 420, 463, 464 and 34 of the Indian Penal Code, 1860. The FIR pertains to alleged tampering and sale in the open market of pharmaceutical products purportedly meant for government supply and names M/s P.P. Enterprises. The matter has been taken cognizance of and is presently pending before the Court of the Judicial Magistrate

First Class (15th Court), Mazgaon, Mumbai as Summons Warrant Case No. 1500028/2021 and is currently at the stage of awaiting report in respect of the remaining accused persons. Kindly refer page 252 of the Red Herring Prospectus.

ANY OTHER INFORMATION AS PER BOOK RUNNING LEAD MANAGER / ISSUER COMPANY – NIL

Disclaimer: The Equity Shares have not been and will not be registered under the U.S. Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares will be offered and sold (i) in the United States only to "qualified institutional buyers", as defined in Rule 144A of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and in compliance with the applicable laws of the jurisdiction where those offers and sales occur.